News - Ampyra

Filter

Current filters:

Ampyra

Popular Filters

US FDA points to seizure risk with Acorda's MS drug Ampyra

25-07-2012

The US Food and Drug Administration has issued a warning about the risk of seizures in patients with…

Acorda TherapeuticsAmpyraNeurologicalNorth AmericaPharmaceuticalRegulation

European Commission gives conditional OK for Biogen Idec’s MS drug Fampyra

26-07-2011

The European subsidiary of US biotech firm Biogen Idec (Nasdaq: BIIB) has received conditional approval…

Acorda TherapeuticsAmpyraBiogen IdecEuropeFampyraNeurologicalPharmaceuticalRegulation

Strong launch for Novartis’ Gilenya despite its time-consuming initiation process; study

02-06-2011

Swiss drug major Novartis' (NOVN: VX) recently-approved oral multiple sclerosis drug Gilenya (fingolimod)…

Acorda TherapeuticsAmpyraGilenyaMarkets & MarketingNeurologicalNovartisPharmaceutical

Australia’s TGA approves Biogen’s Fampyra to improve MS patients walking ability

18-05-2011

The Australian Therapeutic Goods Administration (TGA) has granted approval for USA-based Biogen Idec’s…

AmpyraAsia-PacificBiogen IdecFampyraNeurologicalPharmaceuticalRegulation

Back to top